Organisation paid for research Program year 2025 Source: CMS Open Payments

Precog LLC

Neither a doctor nor a teaching hospital

Research payments

$5,489,540

82 payments

Through program year 2025, Precog LLC is reported as receiving $5,489,540 in research payments, across 82 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$792,811	4
2024	Research	$3,600	1
2023	Research	$48,090	5
2022	Research	$624,220	14
2021	Research	$460,898	20
2020	Research	$1,296,750	23
2019	Research	$2,263,170	15

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $3,952,124 75 payments
GlaxoSmithKline, LLC. $792,811 4 payments
Takeda Pharmaceuticals U.S.A., Inc. $409,996 2 payments
AstraZeneca Pharmaceuticals LP $334,608 1 payment

Studies the money was for Research payments · program years 2019–2025

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Frontline Mantle Cell Lymphoma $2,131,235 44 payments
Phase 2 Study of Venetoclax Abt-199Gdc-0199 in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma As Front Line Therapy $1,363,479 29 payments
0000000000000000000000000000000000000000000000000000000000000000219668 $792,811 4 payments
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma $409,996 2 payments
A Randomized Phase III Study of A Targeted Therapy Combination Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia CLL $380,601 1 payment
MEDI4736 plus chemotherapy as 1st Line therapy in unresectable mesothelioma $334,608 1 payment
Phase 12 Study of Daratumumab, Bortezomib, Dexamethasone With Or Without Venetoclax in Relapsed Refractory Multiple Myeloma With Assessment for T1114 Status $76,810 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.